Abstract Details

Title Sleep complaints are associated with anxiety symptoms and poorer quality of life in Huntington's Disease

Topic Movement Disorders

Presentation(s) P5 - Poster Session 5 (8:00 AM-9:00 AM)

Poster/Presentation
Number 3-011

Objective The current study was designed to investigate sleep quality and its association with clinical symptoms in Huntington's disease.

Background Notwithstanding the high prevalence and the availability of clinical tools, sleep disorders are still not routinely evaluated in patients with HD. Sleep disturbances can seriously affect the quality of life of the patient, caregiver and family. In addition, sleep dysfunction can exacerbate cognitive impairment and mood disorders.

Design/Methods Fifteen patients with HD (51.15±12.66 years, 10F/5M) completed a series of self-reported questionnaires about sleep quality and pattern [Pittsburgh Sleep Quality Index (PSQI)], daytime sleepiness [Epworth Sleepiness Scale (ESS)], cognitive function (NeuroQOLv2.0 Cognition Function), quality of life [HD Quality of Life Questionnaire (HDQoL)] and depressive and anxious symptoms [Hospital Anxiety and Depression Scale (HADS)]. Spearman correlation analyses were performed to ascertain the association between sleep quality and severity of self-perceived clinical symptoms.

Results The primary sleep complaints reported by the patients were related to waking up in the middle of the night or early in the morning; and increased sleep latency. Nine out of the 15 patients (60%) reported the use of sleep medications at least once a week. We did not find any significant association between sleep quality and self-perceived cognitive function or depressive symptoms. Worse sleep quality was associated with greater severity of anxiety symptoms, as observed by the significant correlations between HADS-anxiety score and PSQI global score (rho=0.561,p=0.046) and PSQI components: subjective sleep quality (rho=0.577,p=0.039); sleep latency (rho=0.675,p=0.011); sleep duration (rho=0.586,p=0.035); sleep disturbances (rho=0.733,p=0.004). Importantly, greater severity of sleep latency and sleep disturbances were associated with worse quality of life (rho=0.673,p=0.012; and rho=0.679,p=0.011, respectively).

Conclusions

In our experience, sleep dysfunction in patients with HD is associated with increased anxiety and worse quality of life. Identifying sleep dysfunction in HD is essential as this could significantly impact the optimal management of individuals with Huntington's disease.

Authors/Disclosures
Erin Furr-Stimming, MD, F�鶹��ýӳ�� (University of Texas Health Science Center-Houston) PRESENTER	Dr. Furr-Stimming has received personal compensation for serving as an employee of Help4HD International. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medscape. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MedPage. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for PTC Therapeutics. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Wave Life Sciences. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Latus Bio. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Atalanta Therapeutics. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Furr-Stimming has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for SkyHawk Therapeutics. The institution of Dr. Furr-Stimming has received research support from Roche/Genetech. The institution of Dr. Furr-Stimming has received research support from Uniqure. The institution of Dr. Furr-Stimming has received research support from CHDI. The institution of Dr. Furr-Stimming has received research support from Huntington Study Group/Neurocrine Bioscienes. The institution of Dr. Furr-Stimming has received research support from NIH/University of Iowa. The institution of Dr. Furr-Stimming has received research support from HDSA. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care. Dr. Furr-Stimming has received publishing royalties from a publication relating to health care. Dr. Furr-Stimming has a non-compensated relationship as a Committee member with �鶹��ýӳ�� UES Committee that is relevant to �鶹��ýӳ�� interests or activities.
Will K. Tanigaki, MD	Mr. Tanigaki has nothing to disclose.
M. Agustina Rossetti, PhD (University of Virginia Health System)	Dr. Rossetti has nothing to disclose.
Sudha S. Tallavajhula, MD (TIRR Memorial Hermann Neurological Sleep Disorders Center)	Dr. Tallavajhula has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Zoll Respicardia.
Natalia Pessoa Rocha	Natalia Pessoa Rocha has nothing to disclose.

�鶹��ýӳ��

�鶹��ýӳ��